Mimedx Group Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Mimedx Group Inc 's ROA in the third quarter of 2026?
Mimedx Group Inc recorded a cumulative net loss of $-19 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -6.38%.

However, within the Healthcare sector 265 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2026 from 366 to 626.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	-14.76 %	-3.47 %	14.15 %	29.83 %	30.73 %
Y / Y Net Income Change	-	-	-	104.21 %	106.89 %
Net Income (TTM) in million	-19	6	31	49	41
Return On Assets (TTM)	-6.38 %	1.99 %	9.74 %	15.89 %	14.27 %
MDXG's Total Ranking	# 626	# 366	# 387	# 472	# 322
Total Assets (TTM) in million	272	281	309	343	319
Seq. Total Assets Change	-3.33 %	-8.97 %	-9.92 %	7.52 %	9.47 %
Seq. Net Income Change	-	-	-	-9.31 %	74.13 %

MDXG's 5 Years Annual ROA >> Back to MDXG Management Effectiveness >> Compare MDXG ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 84
Sector	# 266
Overall	# 3034

Return On Assets Statistics
High	Average	Low
46.15 %	-1.47 %	-51.27 %
(Jun 30 2024)		(Jun 30 2019)

News about Mimedx Group Inc Return on Assets ROA

MIMEDX: A Vanguard of Change in Healthcare Costs and Wound Care Innovation,

MIMEDX s Strategic Advocacy and Innovative Developments: A New Era in Wound Care and Medicare Cost ManagementIn recent months, MIMEDX Group Inc has made significant strides in both advocating for cost-effective healthcare practices and innovating within the realm of regenerative medicine. This dual focus not only reflects the company s commitment to the healthcare sector but also serves as a response to the overwhelming costs associated with unproven medical treatments. Notably, MIMEDX s efforts to reining in the rampant spending associated with Medicare coverage for skin substitutes have begun to show promising results, marking a pivotal moment for the company and the healthcare industry at large. Effective Advocacy Against Rising Medicare CostsMIMEDX s advocacy work has led to the planned implementation of revised Local Coverage Determinations (LCDs) that will see the exclusion of more than 200 unproven skin substitutes from Medicare coverage. This initiative is a response to the growing concern over Medicare costs, particularly in the field of dermatological treatments where expenses have spiraled in recent years. The company aims to ensure that taxpayers money is spent responsibly while providing patients access to treatments that are scientifically supported.

Financial Statements
Mimedx Group Inc 's Assets	$ 272 million	MDXG's Balance sheet
Mimedx Group Inc 's Income	$ -9 million	Quarterly MDXG's Income Statement
MDXG's Income by Division		See MDXG's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	29.83 %	10.4 %	39.44 %	-8.78 %	-6.98 %
Total Assets in million	343	264	239	171	188
Y / Y Net Income Change	14.52 %	-27.15 %	-	-	-
Net Income in million	49	42	58	-37	-16
Annual Return On Assets	14.18 %	16.07 %	24.36 %	-21.45 %	-8.74 %

MDXG's 5 Years Annual ROA >> Back to MDXG Management Effectiveness >> Compare MDXG ROA to its Competitors

Comment on MDXG's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA deteriorated to 14.18 %, despite annual net income growth of 14.52 % to $48.58 million, from $42.42 million a year ago, as MDXG's assets increase to $342.65 million, by 14.52 %.

More Return On Assets Ratios
MDXG's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MDXG's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MDXG's Competitors
Subscribers only: Roa for Mimedx Group Inc 's Suppliers
Subscribers only: Return On Assets for MDXG's Customers

You may also want to know
MDXG's Roi	MDXG's Inventory Turnover Ratio	MDXG's Growth Rates	MDXG's Dividend Comparisons
	MDXG's Profitability Ratios	MDXG's Asset Turnover Ratio	MDXG's Dividend Growth
MDXG's Roe	MDXG's Valuation Ratios	MDXG's Financial Strength Ratios	MDXG's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector

ROA

Date modified: 2026-10-29T17:23:01+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.